Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-25 @ 2:42 AM
NCT ID:
NCT02590133
Eligibility Criteria:
Inclusion Criteria:
* Patients have provided a signed Informed Consent Form.
* Histologically confirmed diagnosis of refractory nasopharyngeal carcinoma (the best), or when histology is difficult to obtained, the following clinical diagnosis of refractory nasopharyngeal carcinoma must be confirmed: clear and directional clinical symptoms, at least two kinds of imaging diagnosis on the basis of magnetic resonance (MR), and clear and directional signs.
* Age: 18-70 years old.
* Without dysfunction of heart, lung, liver, kidney, and hematopoiesis, and normal electrocardiogram.
* Karnofsky Performance Scores ≥ 50, Life expectancy ≥ 3 months, tolerance to at least two cycles of chemotherapy.
* At least one measurable tumor based on RECIST 1.1 ( longest diameter: ≥20 mm by CT or magnetic resonance (MR) scan)
* No history of serious allergic to biologic agents
* No history of other malignant tumors, except cured cervical carcinoma in situ and basal skin cancer.
Exclusion Criteria:
* Having the serious cardiovascular disease or other serious complications.
* Woman in pregnancy and breast-feeding.
* Allergic to intervention drugs and dextran.
* Patients participated in clinical trials of other drugs within 4 weeks.
* Use of other chemotherapy drugs, biological treatment, and Chinese medicine anti-cancer drugs at the same time.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT02590133
Study Brief:
Protocol Section:
NCT02590133